Technology Area: Diagnostics
298 Results for 'Diagnostics'
- Technologies (41)
- Collaborations (4)
- Team (0)
- News (193)
- Pages (0)
- Multimedia (60)
- Publications (0)
- Jobs (0)
- Events (0)
Technologies 41
-
PFASense: Fast, In-Field Testing for Forever Chemicals
PFASense is a next-generation diagnostic tool designed to detect toxic ‘forever chemicals’ directly at the source. By combining engineered protein sensors with a portable electrochemical device, it enables real-time, low-cost monitoring of water supplies—providing actionable insights to protect health and guide remediation. -
NeoSense: Sepsis Detection in Newborns
NeoSense is a new test that uses a tiny sample of saliva instead of blood, powered by advanced single-molecule detection and AI. -
COPDx: Rapid diagnostic to triage acute exacerbations
A point-of-care test based on new biomarkers to rapidly identify COPD patients who are high risk of acute exacerbations (AEs), determine the cause, and guide treatment. -
Blood Clot Dx
An ultra-sensitive triage test that identifies patients at risk for blood clots before they happen, enabling proactive treatment to reduce complications and deaths across a wide range of conditions. -
Instrument-Free Molecular Diagnostics
A synthetic biology-based molecular diagnostics platform that enables the creation of low-cost, highly accurate tests for non-clinical settings. -
Crisscross Nanoseed Detection: Nanotechnology-Powered Infectious Disease Diagnostics
This nanotech-based diagnostic platform uses a unique nucleation mechanism that assembles a DNA "nanoseed" in the presence of a pathogen-derived biomarker that then is amplified within 15 minutes to create a signal for easy detection. It is highly robust, and cost-effective, and can be adapted to detect a variety of biomarkers.
Collaborations 4
-
Brigham-Wyss DxA
The Wyss DxA's clinical partners from Brigham and Women’s Hospital identify the most pressing unmet diagnostic needs, provide access to high-quality patient samples for our Biomarker Discovery Laboratory (BDL) and Brigham-Wyss DxA collaborators, and provide invaluable feedback and guidance on the engineering and validation of cost-effective, sensitive, and specific diagnostic tests. -
Biomarker Discovery Laboratory (BDL)
Bridging the diagnostic gap from biomarker discovery to market-ready test kits and instruments through cutting-edge technology development and clinical collaboration. -
Wyss DxA Industrial Participant Program
As the industry-facing component of the Wyss Diagnostics Accelerator, the Industrial Participant Program is a collaboration hub between healthcare testing companies and the scientific and clinical community within the Wyss ecosystem that seeks to compress the timeframe for bringing new, high-impact, diagnostic technologies to market. -
Wyss Diagnostics Accelerator (DxA)
An initiative to enable the fast creation of diagnostic technologies to solve high-value clinical problems through deep collaborations driven by unmet diagnostic needs.
News 193
Multimedia 60
-
Video/Animation20-ish Questions with David Walt20-ish Questions shows a different side of Wyss Institute faculty, touching on aspects of their personal life, hobbies, interests, as well as their research. This round follows David Walt, a Core Faculty member of the Wyss Institute as well as the Hansjörg Wyss Professor of Biologically Inspired Engineering at Harvard Medical School, a Professor of... -
Video/AnimationEngineering Living Materials with Peter Q. NguyenIn this episode of the CoreSpin Podcast Interview Series, host Misha Bagirov sits down with Wyss Senior Scientist Peter Q. Nguyen, Ph.D., to explore how synthetic biology can turn biofilms into useful materials, embed cell-free systems into wearables (like COVID-sensing masks), and program probiotics as future therapeutics. We also talked about the philosophy behind bioengineering,... -
Video/AnimationCan We Stop Stabbing Babies? – Salivary Diagnostics for Sepsis Screening in the NeonateEvery day, across the neonatal care unit, babies are being stabbed to collect their blood for sepsis tests. Adding to this dismal situation, diagnostics developed to assess sepsis in blood are very inaccurate, leading to the unnecessary prescription of antibiotics. Researchers at the Wyss Institute and Brigham and Women’s Hospital have created a more accurate... -
Video/Animation20-ish Questions with Natalie Artzi20-ish Questions shows a different side of Wyss Institute faculty, touching on aspects of their personal life, hobbies, interests, as well as their research. This round follows Natalie Artzi, a new addition to the Wyss Institute’s Core Faculty. Credit: Wyss Institute at Harvard University -
Video/AnimationInnovating Diagnostics to Improve Clinical Care and Patient OutcomesGuest speaker, Sarah-Beth Perullo, shares the immense difficulty she faced in obtaining a diagnosis for her mysterious symptoms. Her story is a sobering reminder of how frequent patient symptoms are dismissed in the medical field. Credit: Wyss Institute at Harvard University -
Video/AnimationWorld of OMICs w/ David Walt & Mike Snyder – BIOS RoundtableThis is a roundtable discussion on the world of OMICs with Wyss Core Faculty member David Walt and Mike Snyder of Stanford University presented by BIOS. David Walt is a Hansjörg Wyss Professor of Biologically Inspired Engineering at Harvard Medical School, a Professor of Pathology at Brigham and Women’s Hospital, a Core Faculty member at...